Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Gaps in the achievement of effectiveness of HCV treatment in national VA practice.

Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB.

J Hepatol. 2012 Feb;56(2):320-5. doi: 10.1016/j.jhep.2011.05.032. Epub 2011 Jul 12.

PMID:
21756855
2.

Predictors of response of US veterans to treatment for the hepatitis C virus.

Backus LI, Boothroyd DB, Phillips BR, Mole LA.

Hepatology. 2007 Jul;46(1):37-47.

PMID:
17567830
3.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
4.

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A.

Dig Dis Sci. 2011 Aug;56(8):2439-48. doi: 10.1007/s10620-011-1746-3. Epub 2011 Jun 2.

PMID:
21633833
5.

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.

Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC.

Arthritis Rheum. 2002 Dec;46(12):3317-26.

6.

Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.

Hansen N, Obel N, Christensen PB, Kjær M, Laursen AL, Krarup HB, Møller A, Schlichting P, Bukh J, Weis N; Danish Database for Hepatitis B and C (DANHEP)- group.

BMC Infect Dis. 2011 Jun 21;11:177. doi: 10.1186/1471-2334-11-177.

7.

[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].

Kim CH, Park BD, Lee JW, Kim YS, Jeong S, Lee DH, Kim HG, Shin YW, Kwon KS, Lee JI.

Korean J Hepatol. 2009 Mar;15(1):70-9. doi: 10.3350/kjhep.2009.15.1.70. Korean.

8.

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID:
18756436
9.

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.

Mach TH, Cieśla A, Warunek W, Janas-Skulina U, Cibor D, Owczarek D, Ciećko-Michalska I.

Pol Arch Med Wewn. 2011 Dec;121(12):434-9.

10.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1. doi: 10.1016/j.cgh.2011.03.004. Epub 2011 Mar 11.

PMID:
21397729
11.

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.

Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T.

Gastroenterology. 2011 Nov;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019. Epub 2011 Jul 22.

PMID:
21784046
12.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Hepatology. 2008 Jun;47(6):1884-93. doi: 10.1002/hep.22319.

PMID:
18508296
13.

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.

Carlsson T, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E, Weiland O.

J Viral Hepat. 2005 Sep;12(5):473-80.

PMID:
16108761
14.

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K.

Scand J Gastroenterol. 2012 Sep;47(8-9):1115-9. doi: 10.3109/00365521.2012.694905. Epub 2012 Jun 7.

PMID:
22670704
15.

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J.

J Hepatol. 2006 Jan;44(1):97-103. Epub 2005 Nov 7.

PMID:
16290907
16.

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M, Murata M, Sawayama Y, Hayashi J.

BMC Gastroenterol. 2010 Apr 16;10:38. doi: 10.1186/1471-230X-10-38.

17.

[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].

He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):34-7. doi: 10.3760/cma.j.issn.1007-3418.2011.01.010. Chinese.

PMID:
21272456
18.
19.

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.

Inglot M, Pawlowski T, Szymczak A, Malyszczak K, Zalewska M, Radkowski M.

Postepy Hig Med Dosw (Online). 2013 Mar 11;67:186-91.

20.

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.

Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk